Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND CODEINE PHOSPHATE vs TRANXENE SD
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal inhibition.
Mild to moderate pain,Pain accompanied by fever
Anxiety disorders,Short-term relief of anxiety symptoms,Acute alcohol withdrawal,Preoperative sedation (adjunctive),Partial seizures (adjunctive, off-label)
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Oral: 11.25-22.5 mg once daily (sustained-release formulation).
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Terminal elimination half-life of nordazepam (active metabolite) is 30–100 hours (mean 50 hours); clorazepate itself has a short half-life (~2 hours) due to rapid conversion.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Hepatic via conjugation and oxidative metabolism; primary metabolite is desmethyldiazepam (active); CYP450 involvement (CYP3A4 and CYP2C19).
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Renal excretion of conjugated metabolites, with less than 1% unchanged drug; approximately 30% excreted in feces via biliary elimination.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
97–98% bound to albumin; nordazepam is highly protein-bound.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
0.9–1.4 L/kg for clorazepate; nordazepam Vd approximately 0.8–1.2 L/kg, indicating extensive tissue distribution.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
Oral: 100% (prodrug fully converted); no parenteral formulation.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
GFR <10 m L/min: Reduce dose by 25-50% and consider avoidance due to accumulation of active metabolites.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Child-Pugh Class B or C: Reduce dose by 50% or avoid use; monitor for excessive sedation.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Not recommended for patients <18 years due to lack of safety and efficacy data.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Reduce initial dose by 50% (e.g., 11.25 mg once daily or less), titrate slowly, and monitor for falls and cognitive impairment.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Risk of abuse, misuse, and addiction,Dependence and withdrawal reactions,CNS depressant effects (impairment of driving/operating machinery),Respiratory depression (especially with opioids),Glaucoma (narrow-angle) use cautiously,Suicidal ideation (pre-existing depression)
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Hypersensitivity to clorazepate or other benzodiazepines,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concomitant use with opioids (in some contexts)
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Food may delay but does not significantly reduce absorption. Avoid grapefruit juice as it may inhibit CYP3A4, increasing nordazepam levels. Avoid alcohol completely.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
First trimester: Increased risk of congenital malformations (oral clefts) reported with benzodiazepine use; data specifically for clorazepate limited but class effect assumed. Second/third trimester: Exposure may cause fetal CNS depression, hypotonia, respiratory depression, and withdrawal symptoms (e.g., jitteriness, hypertonia) in neonates.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Clorazepate is excreted into breast milk; M/P ratio approximately 0.2. Infant exposure likely low but may cause sedation. Use with caution; monitor infant for drowsiness and poor feeding. Consider alternative if high maternal doses or prolonged use.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Increased volume of distribution and enhanced hepatic metabolism in pregnancy may lower serum clorazepate levels; consider dose increase if therapeutic effect inadequate. Avoid in first trimester if possible; use lowest effective dose in later trimesters. Taper gradually before delivery to minimize neonatal withdrawal.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
TRANXENE SD (clorazepate dipotassium) is a long-acting benzodiazepine with a slow onset, making it less suitable for acute panic but effective for generalized anxiety. Its active metabolite, nordazepam, has a half-life of 40-100 hours, allowing once-daily dosing. Monitor for accumulation in elderly or hepatic impairment. Use with caution in patients with a history of substance abuse due to dependence risk.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not stop abruptly; reduce dose gradually to avoid withdrawal symptoms (e.g., anxiety, insomnia, seizures).,Avoid alcohol and other CNS depressants (e.g., opioids, sedatives) as they increase sedation and respiratory depression risk.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how the drug affects you.,Report any unusual changes in mood, thoughts, or behavior (e.g., depression, suicidal thoughts).,Use effective contraception if of childbearing potential due to fetal harm risk; notify prescriber if pregnant or breastfeeding.
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND CODEINE PHOSPHATE vs TRANXENE SD, answered by our medical review team.
ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. TRANXENE SD is a Benzodiazepine Anxiolytic that works by Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND CODEINE PHOSPHATE and TRANXENE SD depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of TRANXENE SD is: Oral: 11.25-22.5 mg once daily (sustained-release formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND CODEINE PHOSPHATE and TRANXENE SD in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. TRANXENE SD is classified as Category C. First trimester: Increased risk of congenital malformations (oral clefts) reported with benzodiazepine use; data specifically for clorazepate limited but class effect assumed. Seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.